CompoAtlas

Mini Thin 25 mg Ephedrizine

En vente sur le marché américain (selon le DSLD)

DBI Distribution, food supplement from the US market

Mini Thin 25 mg Ephedrizine (DBI Distribution), a food supplement au code-barres 010684490042, is described by its US market label. If sold in France, it would be subject to 3 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
DBI Distribution
Barcode
010684490042
Form
Tablet
One serving
1 tablet
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Microcrystalline Cellulose, Dibasic Calcium Phosphate, Sodium Starch Glycolate, Stearic Acid, Magnesium Stearate, Silica
Ingredient (as written, in English)CategoryPer serving
Proprietary BlendBlend208 mg
Caffeine AnhydrousOther substancenot stated
Corynanthe extract (Pausinystalia johimbe)Plantnot stated
Kola NutPlantnot stated
Green Tea (Camellia sinensis)Plantnot stated
Ephedrizine Proprietary BlendBlend25 mg
3,7-Dihydro-3, 7-Dimethyl-1H-Purine-2, 6-DioneOther substancenot stated
Yerba Mate (Ilex paraguariensis)Plantnot stated
Bacopa monnieri (Bacopa monnieri)Plantnot stated
D-Aspartic AcidAmino acidnot stated
Pilocarpus pennatifoliusPlantnot stated
White Willow (Salix alba)Plantnot stated
L-Arginine Ethyl Ester DihydrochlorideAmino acidnot stated
Choline BitartrateVitaminnot stated
Beta-AlanineAmino acidnot stated
DMAEOther substancenot stated
L-AlanineAmino acidnot stated
Capsicum (Capsicum annuum)Plantnot stated
Sodium PyruvateOther substancenot stated
Guanidino Propionic AcidOther substancenot stated
HordenineOther substancenot stated

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • White Willow
    Read the warning, when it applies and the studies cited

    WILLOW BARK

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have asthma or peptic ulcer disease (EMA 2017).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or products containing salicylates (e.g., acetylsalicylic acid or non-steroidal anti-inflammatory drugs) (EMA 2017).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are allergic to salicylates (EMA 2017; Brinker 2010; Wichtl 2004, ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000)

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 March 2024

  • Capsicum
    Read the warning, when it applies and the studies cited

    CAYENNE - CAPSICUM ANNUUM Oral

    Cautions and warnings

    Condition of application: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Cautions and warnings

    Condition of application: All products.

    For external use only (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 March 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : DBI Distribution

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2020. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line